• FirefoxUpgrade to the new Firefox »
  •  Dow Down0.79% Nasdaq Up0.16%

    More On ONC.TO



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Oncolytics Biotech Inc. (ONC.TO)

    0.57 0.00(0.00%) Jan 23, 3:22PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Oncolytics Biotech Inc.
    1167 Kensington Crescent NW
    Suite 210
    Calgary, AB T2N 1X7
    Canada - Map
    Phone: 403-670-7377
    Fax: 403-283-0858
    Website: http://www.oncolyticsbiotech.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Oncolytics Biotech Inc.

    Key Executives 
    Dr. Bradley G. Thompson Ph.D.,
    Exec. Chairman, Chief Exec. Officer and Pres
    Mr. Kirk J. Look CA,
    Chief Financial Officer, Principal Accounting Officer and Chief Financial Officer of Oncolytics Biotech (U.S.) Inc.
    Dr. Matthew C. Coffey Ph.D.,
    Chief Operating Officer and Director
    Dr. George M. Gill M.D.,
    Chief Safety Officer and Sr. VP of Clinical & Regulatory Affairs
    Dr. Alan J. Tuchman M.D., MBA, (FANN), 68
    Chief Medical Officer and Sr. VP of Medical & Clinical Affairs
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.